TB-500

At a glance

TB-500 vs. thymosin beta-4: the distinction that matters

TB-500 and thymosin beta-4 are routinely treated as interchangeable online. They are not. Understanding this distinction is the single most important thing you can learn about TB-500.

Thymosin beta-4 is a 43-amino-acid protein found naturally in virtually all human cells, with especially high concentrations in platelets and wound fluid. It was first isolated from calf thymus tissue by Allan Goldstein and colleagues in the 1960s, and its full sequence was determined in 1981.^[1] It has been studied in multiple clinical trials for wound healing, dry eye, cardiac repair, and corneal injuries.

TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) corresponding to residues 17-23 of thymosin beta-4 — the region identified as the actin-binding domain.^[15] It was developed commercially in the early 2000s, primarily for use in equine veterinary medicine.

Here is why this matters:

• All human clinical trials (wound healing, dry eye, cardiac repair) used full-length thymosin beta-4, not TB-500
• The TB-500 fragment has zero registered human clinical trials
• The fragment is missing 36 of the 43 amino acids in the parent protein, including domains that may have additional biological functions
• No human pharmacokinetic data exists for TB-500 — we don't know how it's absorbed, distributed, metabolized, or eliminated in humans
• Whether a 7-amino-acid fragment replicates the effects of a 43-amino-acid protein is a genuine scientific question, not an assumption

What is TB-500?

TB-500 is a synthetic peptide — a short chain of 7 amino acids — that corresponds to the actin-binding domain of thymosin beta-4. The sequence (LKKTETQ) is typically sold in its N-terminally acetylated form (Ac-LKKTETQ), which may improve stability.

Thymosin beta-4, the parent molecule, is one of the most abundant small proteins inside human cells. It plays a critical role in regulating actin, the structural protein that controls cell shape, movement, and division. When tissue is injured, platelets release thymosin beta-4 at the wound site, where it helps coordinate the repair process — promoting cell migration, new blood vessel formation, and reducing inflammation.

TB-500 gained popularity through equine veterinary medicine, where it has been widely used for soft tissue injury recovery in racehorses. This practical veterinary use is the origin of much of the dosing knowledge in circulation, though controlled equine trials are also limited.

The compound is not extracted from thymus tissue — it is synthesized in a laboratory. The name "TB-500" is a commercial designation, not a scientific one.

How it works

In plain terms, TB-500 contains the specific region of thymosin beta-4 that controls actin — one of the most important structural proteins in your cells. By regulating actin, it influences how cells move, divide, and organize themselves during tissue repair.^[4]

Think of actin as cellular scaffolding. When tissue is damaged, cells need to reorganize their scaffolding to migrate to the wound site, build new blood vessels, and lay down new tissue. TB-500's actin-binding domain appears to facilitate this process — based on what we've observed in animal models and in vitro studies.

What the research says

Thymosin beta-4 has been published in Nature twice and studied in multiple Phase II and one Phase III clinical trial. TB-500 — the fragment that people actually buy — has zero human trials. This is the central tension of the TB-500 evidence base.

Research timeline

Human clinical trials

There are zero human clinical trials for the TB-500 fragment. All human data comes from studies of full-length thymosin beta-4. Here is what those trials found — with the crucial caveat that they used a different molecule:

Animal studies

The preclinical literature for thymosin beta-4 is extensive and high-quality — including two publications in Nature, which is rare for any peptide in this space. Key findings:

What the evidence shows

People come to TB-500 with specific questions. Here's what the published research actually tells us about the most common areas of interest:

Safety & side effects

What research shows

For full-length thymosin beta-4 (the parent molecule): Clinical trials involving hundreds of participants reported the peptide as safe and well-tolerated. A Phase I study in 84 healthy volunteers found no dose-limiting toxicities or serious adverse events.^[11] Phase II wound healing and dry eye trials similarly reported no significant safety concerns.

For TB-500 (the fragment): No formal human safety data exists. No preclinical toxicology studies specific to the TB-500 fragment have been published in peer-reviewed literature. Everything we know about TB-500 safety is extrapolated from the parent molecule or from community self-reports.

Community-reported side effects

Among people who have used TB-500 outside of clinical settings, commonly reported effects include:

• Water retention and bloating (especially during initial weeks)
• Headache (typically resolves after 1-2 weeks)
• Fatigue and lethargy
• Flu-like symptoms initially
• Injection-site redness, swelling, or tenderness
• Mild nausea (occasional, more common at higher doses)
• Lightheadedness (rare)

These are self-reported and not from controlled studies. They should be taken as signal, not as definitive safety data.

Theoretical risks

How people use it

TB-500 is most commonly discussed in the context of injury recovery, particularly for muscle, tendon, and ligament injuries. Here's what the landscape of use looks like — with important caveats.

Administration routes

• Subcutaneous injection (most common): Unlike BPC-157, TB-500 is considered systemically active regardless of injection location. People typically inject in the abdomen, outer thigh, or upper arm — the injection site does not need to be near the injury.
• Intramuscular: Used by some for deeper tissue injuries.

Common stacking context

In community practice, TB-500 is often discussed alongside other peptides:

• TB-500 + BPC-157 — the "Wolverine stack," targeting healing through complementary mechanisms (actin regulation + angiogenesis). No clinical data supports this combination.
• TB-500 + GHK-Cu — discussed for comprehensive tissue regeneration. Anecdotal reports only.
• TB-500 + CJC-1295/Ipamorelin — discussed for GH-mediated recovery alongside direct tissue repair. No controlled studies.

All stacking protocols are community-derived and have not been studied in any controlled setting.

If you plan to reconstitute peptides, see our reconstitution guide for safety-first preparation instructions.

Legal & regulatory status

As of August 15, 2026:

FDA status

TB-500 is not FDA-approved for any indication, and it is not on the 503A Bulks List.

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding TB-500 free base and TB-500 acetate to that list. The reported tally was 8 yes, 6 no, 1 abstain. FDA has published no official tallies, minutes, or transcript, so those numbers come from legal and trade press reporting rather than from FDA.^[18]

The committee voted against FDA's own scientists, whose multidisciplinary review team recommended that none of the seven peptides on the agenda be added to the list.^[17]

FDA made the fragment problem an opening argument

The most useful thing to come out of the meeting for TB-500 buyers had nothing to do with the vote. FDA opened the two days with a dedicated presentation titled "FDA Bulk Drug Substance Discussion of Conflated Bulks and Common Name Challenges" — about trade names that map to different amino acid sequences and different molecular weights depending on the supplier, so that a prescription does not actually identify what the patient receives.^[17]

That is precisely the problem this page has flagged from the start. "TB-500" is used commercially for both the 7-amino-acid acetylated fragment (Ac-LKKTETQ) and for full-length 43-amino-acid thymosin beta-4 — two different molecules with two different evidence bases.^[15] FDA's own agenda for the meeting sidestepped the question entirely, naming the substance only as "TB-500 (free base)" and "TB-500 acetate" with no sequence attached.^[16]

The practical implication is unchanged by the vote: if a vendor or clinic cannot tell you which molecule is in the vial, and show you a certificate of analysis that matches, you cannot know which body of research applies to what you are buying.

The use FDA evaluated is wound healing — not tendon repair, athletic recovery, or general tissue regeneration.^[16]

For the full tallies, the roster, and what has to happen next, see The July 2026 PCAC peptide vote.

WADA / USADA status

Thymosin beta-4 and its derivatives — including TB-500 — are prohibited at all times under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). The in-force 2026 Prohibited List explicitly names "Thymosin-beta4 and its derivatives e.g. TB-500" under S2.3 (Growth Factors and Growth Factor Modulators). Athletes testing positive face a standard 4-year ban.^[14]

WADA's 2027 Prohibited List was still in stakeholder consultation as of August 15, 2026 and had not been published. No change to Section S2 was visible in the draft materials we could review.

International status

TB-500 is not approved for clinical use in any country. Full-length thymosin beta-4 has been studied in clinical trials by RegeneRx Biopharmaceuticals (US) and Beijing Northland Biotech (China), but has not received regulatory approval anywhere. TB-500 is available as a "research chemical" in most jurisdictions and is widely used in equine veterinary medicine (though banned by some racing commissions).

How TB-500 compares to BPC-157

TB-500 and BPC-157 are the two most commonly discussed healing peptides — and are frequently combined in the "Wolverine stack." Here's how their evidence profiles compare:

Both peptides share the same fundamental limitation: very limited human clinical data. Where they differ is in structure and mechanism:

• BPC-157 has more animal studies (100+), but nearly all from a single lab. It works through angiogenesis and growth factor signaling, and shows the strongest evidence for GI protection and tendon repair.
• TB-500 has fewer studies overall but benefits from higher-quality preclinical research (two Nature papers) conducted by multiple independent labs. Its parent molecule has more advanced human trials. It works through actin regulation and cell migration.

The "Wolverine stack" rationale is that these complementary mechanisms — BPC-157's angiogenesis plus TB-500's actin regulation — might produce synergistic healing effects. This is mechanistically plausible but has zero clinical evidence supporting it. The combination has never been studied in any controlled setting, in any species.